NCT00234052View on ClinicalTrials.gov

Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 28, 2005

Primary Completion Date

March 1, 2011

Study Completion Date

November 28, 2011

Conditions
Lung Cancer
Interventions
BIOLOGICAL

bevacizumab

5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)

DRUG

carboplatin

Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)

DRUG

pemetrexed

Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)

Trial Locations (5)

60426

Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey

60612

Rush Cancer Institute at Rush University Medical Center, Chicago

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

60201-1781

Evanston Northwestern Healthcare - Evanston Hospital, Evanston

60068-1174

Advocate Lutheran General Cancer Care Center, Park Ridge

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT00234052 - Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter